



# MINUTES

Utah Department of Health  
Drug Utilization Review Board

**THURSDAY, January 8, 2015**  
**7:00 a.m. to 8:30 a.m.**  
**Cannon Health Building**  
**Room 125**

**Board Members Present:**

**Tony Dalpiaz, PharmD.**  
**Michael Symond, M.D.**  
**Keith Tolman, M.D.**

**Mr. Kumar Shah**  
**George Hamblin, PharmD**  
**Susan Siegfried, M.D**

**Board Members Excused:**

**Jennifer Brinton, MD**  
**Mark Balk, PharmD.**

**Jay Aldus, DDS**  
**Kyle Jones, M.D.**

**Dept. of Health/Div. of Health Care Financing Staff Present:**

**Robyn Seely, Pharm.D**  
**Trevor Smith C.Ph.T.**  
**Heather Santacruz, R.N .**

**Lisa Hunt, RPh**  
**Merelynn Berrett, R.N.**

**Other Individuals Present:**

**Gary Oderda, UofU**  
**Sumar Bieda, Purdue**  
**Joanita Lake, UofU**  
**Dave Felt, DSAMH**  
**Cody Ball, Select Health**  
**Chris Draheim, Teva**  
**Luke Weadon, Biogen**

**Sushma Patel, AstraZeneca**  
**Kelly Ponce, AstraZeneca**  
**Charissa Anne, J&J**  
**Scott Larson, BMS**  
**Deron Grothe, Teva**  
**Lori Howarth, Bayer**

---

**Meeting conducted by: Tony Dalpiaz, Pharm.D.**

---

- 1. Welcome** – Tony Dalpiaz opened the meeting.
- 2. Housekeeping** – Robyn Seely welcomed everyone to the meeting and reminded everyone to sign in. She said that there are no petitions for the board today.
- 3. P&T Committee report** – Lisa Hunt said that the P&T committee will review substance abuse treatment agents during the January meeting. She also said that the 2015 PDL is live on the Utah Medicaid website now.
- 4. Approval of prior meeting minutes** – Keith Tolman made a motion to approve the December meeting minutes. Mike Symond seconded the motion. All in favor.

**5. Multiple Sclerosis Infusion Agents (*Mitaxantrone and Natalizumab*)** – Joanita Lake from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about MS drugs in this class. Data was also presented about the utilization of the drugs in the Utah Medicaid population in previous years.

**6. Public Comment**

- a. Luke Weadon (Tysabri, Biogen ). He presented information about Tysabri and offered to answer questions from the board.

**7. Board Discussion on Mitaxantrone and Natalizumab**

- a. Robyn Seely presented the current PA criteria sheet for Tysabri. She said that she suggests removing the criteria as the drug is a part of a REMs program that will ensure proper and correct usage of the drug.
- b. Keith Tolman made a motion to remove the current PA criteria on Tysabri. George Hamblin seconded the motion. All in favor.

**8. Multiple Sclerosis Self-Injectable Agents (*Interferon  $\beta$ -1a, Peginterferon  $\beta$ -1a, Interferon  $\beta$ -1b, galatiramer acetate*)** – Joanita Lake from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about MS drugs in this class. Data was also presented about the utilization of the drugs in the Utah Medicaid population in previous years.

**9. Public Comment**

- a. Luke Weadon (Avonex and Plegrity, Biogen ). He presented information about Avonex and Plegrity and offered to answer questions from the board.

**10. Board Discussion on Self-Injectable Agents**

- a. Robyn presented possible PA criteria to the board.
- b. George Hamblin asked if there are any current PA criteria on the drugs. There is not.
- c. The board discussed if a PA is required, as they are not subject to misuse or abuse.
- d. George Hamblin made a motion to keep the current status on the drugs of not requiring a Prior Authorization. Kumar Shah seconded the motion. All in favor.

**11. Meeting Adjourned**

The next DUR Board meeting is scheduled for Thursday, February 12<sup>th</sup>. Multiple Sclerosis agents (Part 2) will be discussed.

Minutes prepared by Trevor Smith.

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)